Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population
International Journal of Urology · 2026
DOI: 10.1111/iju.70584 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yuto Matsushita und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
Avelumab maintenance therapy following platinum‐based chemotherapy is recommended as an alternative treatment in patients with locally advanced or metastatic urothelial carcinoma; however, real‐world data are limited, and no predictive system has been established to identify suitable candidates for avelumab at the initiation of chemotherapy.
Methods
This retrospective study analyzed 324 patients with locally advanced or metastatic urothelial carcinoma who received platinum‐based chemotherapy. Patients were divided into three groups: 130 who received avelumab (avelumab group), 58 who did not experience disease progression on chemotherapy within 4 cycles but did not receive avelumab (PBC‐only group), and 136 who experienced disease progression on chemotherapy within 4 cycles (PBC‐PD group). Oncological outcomes were compared among the groups, and a system for predicting the maintained response to chemotherapy for 4 or more cycles was explored.
Results
The avelumab group had significantly longer overall survival than the other two groups. After propensity score matching, overall survival was significantly longer in the avelumab group than in the PBC‐only group. Lymph node‐only metastasis and a low neutrophil‐to‐lymphocyte ratio were identified as predictive factors for maintaining response to chemotherapy. Among patients with these two factors (favorable group), 81.1% maintained a response, and those who received avelumab maintenance therapy showed that the median overall survival was 33.4 months from initiation of chemotherapy.
Conclusions
The survival benefit of avelumab following chemotherapy compared to chemotherapy alone was confirmed. In the favorable group, avelumab following chemotherapy may be a valuable option if they are ineligible or unwilling to receive the preferred regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Urology, University of Miyazaki, Miyazaki, Japan.
- Department of Urology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
- Department of Urology, Aichi Medical University, Nagakute, Aichi, Japan.
- Department of Urology, Tokushima University, Graduate School of Biomedical Sciences, Tokushima, Japan.
ORCID-Profile: Yuto Matsushita, Yuki Kita, Shotaro Nakanishi, Shingo Hatakeyama, Keiichiro Mori, Hiroshi Kitamura, Takahiro Kimura, Yoshiyuki Matsui, Makito Miyake, Takashi Kobayashi, Teruo Inamoto
Zitieren
APA
Matsushita, Y., Kita, Y., Mukai, S., Joraku, A., Kobayashi, I., Daizumoto, K., Sano, T., Nakanishi, S., Watanabe, J., Hatakeyama, S., Goriki, A., Hazama, T., Nishiyama, N., Mori, K., Kitamura, H., Kimura, T., Matsui, Y., Miyake, M., Kobayashi, T., …, & Japanese Urological Oncology Group (2026). Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population. International Journal of Urology. https://doi.org/10.1111/iju.70584
Vancouver
Matsushita Y, Kita Y, Mukai S, Joraku A, Kobayashi I, Daizumoto K, et al. Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population. International Journal of Urology. 2026. doi:10.1111/iju.70584
BibTeX
@article{Matsushita2026,
author = {Matsushita, Yuto and Kita, Yuki and Mukai, Shoichioro and Joraku, Akira and Kobayashi, Ikuo and Daizumoto, Kei and Sano, Tomoyasu and Nakanishi, Shotaro and Watanabe, Jun and Hatakeyama, Shingo and Goriki, Akihiro and Hazama, Tatsuya and Nishiyama, Naotaka and Mori, Keiichiro and Kitamura, Hiroshi and Kimura, Takahiro and Matsui, Yoshiyuki and Miyake, Makito and Kobayashi, Takashi and Inamoto, Teruo and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
title = {Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70584}
}
EUVIMED